Dominic Pilon
Vice President at Analysis Group
Data updated
Research Footprint
Dominic Pilon appears in 5 tracked papers (2023–2025), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance (12 citations).
Frequent co-authors: Kruti Joshi, Maryia Zhdanava and Aditi Shah.
Background & Research
Dominic Pilon is a Vice President at Analysis Group in Montreal, where he specializes in biostatistics and health economics and outcomes research. His work includes retrospective claims analyses, electronic medical record studies, survey research, and clinical trial data analyses across major depressive disorder, schizophrenia, and other therapeutic areas. He has presented at major scientific meetings including the American Psychiatric Association and has published extensively in peer-reviewed journals.
Key Impact
He is a health economics and outcomes research specialist whose real-world evidence studies have been widely used in esketamine and other psychiatric treatment research.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Dominic Pilon is associated with.